NCT00237172View on ClinicalTrials.gov

Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

September 30, 2002

Primary Completion Date

July 31, 2005

Conditions
Gastrointestinal Stromal Tumors
Interventions
DRUG

Imatinib Mesylate

once daily

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY